Deciding which is causing a symptom change is one of the biggest challenges in managing ABPA and asthma together, since the two conditions often overlap and interact.

Here’s a breakdown to help you tell which condition might be driving your symptoms — though in many cases, they contribute together:

🧭 ABPA vs Asthma: Symptom Clues

Symptom More Likely ABPA More Likely Asthma
Increased sputum / mucus plugging ✅ Thick, sticky, brownish mucus common in ABPA ❌ Asthma usually has dry cough, not much mucus
Sudden worsening after steroid reduction ✅ Flare of ABPA likely ❌ Asthma usually responds to inhalers unless severe
Persistent wheeze despite good inhaler use ✅ Could suggest ABPA inflammation or mucus ✅ Asthma too, but should improve with bronchodilators
Raised total IgE or eosinophils ✅ Strong ABPA clue ✅ Can happen in asthma too, but less extreme
Fever, malaise, or feeling ‘infected’ ✅ Possible in ABPA flares ❌ Not typical in asthma
Crackles or signs on chest exam ✅ More common in ABPA with bronchiectasis ❌ Asthma usually has wheeze, not crackles
Daily productive cough ✅ Common in ABPA and bronchiectasis ❌ Asthma usually has dry, episodic cough

🧪 How Doctors Distinguish Them

  • Blood tests: Total IgE, eosinophils, Aspergillus-specific IgE

  • Sputum cultures: To check for Aspergillus or secondary infection

  • Spirometry: Looks for reversible airflow obstruction (asthma)

  • Chest CT scan: Shows mucus plugging, central bronchiectasis (ABPA)

  • Steroid response test: Asthma often improves rapidly; ABPA needs longer or higher doses

🔄 Important: They Often Coexist

  • Many people with ABPA have asthma first.

  • ABPA may worsen asthma symptoms by causing inflammation, mucus plugging, and airway damage.

  • Treating ABPA (with steroids, antifungals, or omalizumab) often improves asthma control.

✅ What You Can Do

  • Keep a symptom diary: track mucus, breathlessness, triggers, and response to inhalers or steroids.

  • Ask your care team to help you track your IgE and eosinophils over time.

  • If you’re on biologics (e.g., omalizumab), monitor exacerbation frequency and inhaler needs.

Print Friendly, PDF & Email

Latest News posts

Print Friendly, PDF & Email